Allergy Therapeutics plc (AIM: AGY)

Market Cap	204.96M
Revenue (ttm)	53.26M
Net Income (ttm)	-50.22M
Shares Out	4.77B
EPS (ttm)	-0.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	928,299
Open	3.800
Previous Close	4.300
Day's Range	3.800 - 4.400
52-Week Range	1.200 - 6.300
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 27, 2024

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, an...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2004
• Employees: 612
• Stock Exchange: London Stock Exchange AIM
• Ticker Symbol: AGY

Financial Performance

In 2023, Allergy Therapeutics's revenue was 59.59 million, a decrease of -18.11% compared to the previous year's 72.77 million. Losses were -43.07 million, 212.7% more than in 2022.